Stock Track | Iovance Stock Plunges Despite Strong Q3 Results and Positive Updates
Iovance Biotherapeutics, Inc. saw its stock price plunge by 9.61% in after-hours trading on November 7, 2024, despite reporting strong financial results and positive corporate updates for the third quarter and first nine months of 2024.The biotechnology company announced total revenue of $58.6 million in the third quarter, primarily driven by $42.1 million in sales of its newly launched cancer therapy Amtagvi and $16.5 million in sales of Proleukin, which is used in the Amtagvi treatment regim